(AOF) – Quantum Genomics, a biotech developing drugs that act directly on the brain, announces that its managing director since 2018 Jean-Philippe Milon has also been appointed chairman of the board of directors to replace Lionel Sgard, who has been dismissed. Founding boss of the company, Lionel Segard held the positions of Chairman and CEO from 2006 to 2018.
Following the negative results of the phase III Fresh study in resistant hypertension and the decision to prematurely stop the second phase III Refresh study in this same indication and more broadly the development of firibastat in cardiology, Quantum Genomics implemented a staff restructuring plan involving the disappearance of functions related to the marketing process for firibastat in cardiology.
Finally, Quantum Genomics has entered into discussions with several Biotech and Medtech companies, listed and unlisted, and is studying all the opportunities and methods of possible mergers to build a new business project.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.